32SY)4?-6Y@6I-U~)39N'U(,=.*EE
SYSTEM PROCESSING...
32SY)4?-6Y@6I-U~)39N'U(,=.*EE
SYSTEM PROCESSING...
Posted: 2025-09-05 12:26:25 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-09-05 12:26:51 UTC
Verified By
Rollup News
BioNTech's experimental breast cancer drug, developed with Duality Biotherapeutics, outperformed Roche's Kadcyla in a late-stage trial, reducing the likelihood of cancer worsening or death in patients.
BioNTech's first big win in cancer with an experimental breast cancer drug.
The drug outperformed Roche’s Kadcyla in a late-stage trial.
Potential regulatory approval for BioNTech's cancer compound.
Validation for Duality Biotherapeutics, with a stock increase of 280% since its April debut.
Cancers had spread or couldn’t be surgically removed after older therapies failed.
Trial covered 228 Chinese patients.